No Data
No Data
Are Investors Undervaluing Sanofi (SNY) Right Now?
Press Release: Availability of the Q3 2024 Aide Mémoire
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Sanofi:la Presidencia Polaca De La UE Allana El Camino Para Una Industria Farmacéutica Competitiva